Narrative review in the current role of angiotensin receptor-neprilysin inhibitors

Heart failure (HF) accounts for a tremendous burden on health care systems and the society. Since the landmark PARADIGM-HF trial, sacubitril/valsartan, the first in the class of angiotensin receptor neprilysin inhibitor (ARNI) showed superiority to enalapril in patients with HF with reduced ejection...

Descripción completa

Detalles Bibliográficos
Autores principales: Cruz Rodriguez, Jose B., Cu, Cameron, Siddiqui, Tariq
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review article on Heart Failure Update and Advances in 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039652/
https://www.ncbi.nlm.nih.gov/pubmed/33850915
http://dx.doi.org/10.21037/atm-20-4038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039652/
https://www.ncbi.nlm.nih.gov/pubmed/33850915
http://dx.doi.org/10.21037/atm-20-4038

Ejemplares similares